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Summary
Objective: To compare the safety and effectiveness of a high molecular weight hyaluronan produced by biological fermentation (Bio-HA) with
those of avian-derived hyaluronan that uses cross-linking to achieve high molecular weight (CL-HA).
Design: This was a prospective, multicenter, randomized, double-blind trial evaluating patients with conﬁrmed osteoarthritis of the knee. The
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Index) pain subscale was the primary effectiveness measure (vi-
sual analog scale). Both products were administered via three weekly injections, with follow-up evaluations at weeks 3, 6 and 12. Acetamin-
ophen was permitted as rescue medication and quantitated by pill counts.
Results: Analyses were performed on the intent-to-treat population, deﬁned as all patients receiving at least one injection. Of the 321 patients
randomized to treatment, 314 patients (98%) completed the ﬁnal study assessment. Improvement in the average WOMAC Index pain score
was 29.8 mm (61.6%) for Bio-HA and 28.8 mm (54.9%) for CL-HA, meeting the prospective criteria for non-inferiority. For the secondary
outcome measures, statistically signiﬁcant differences favored Bio-HA for the number of patients requiring acetaminophen (PZ 0.013) and
patient global satisfaction evaluations (PZ 0.03). Local reactions differed between the products in that 15 effusions were reported in 13
CL-HA patients (8.1%) after injection, compared to one effusion (0.6%) after Bio-HA injection (PZ 0.0015).
Conclusion: The effectiveness of Bio-HA was not inferior to that of CL-HA. The signiﬁcantly higher incidence of post-injection effusion in
the CL-HA group provides a safety advantage for Bio-HA. These data suggest that Bio-HA has an improved beneﬁt-risk proﬁle compared
with CL-HA.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Intra-articular hyaluronan (IA-HA) injections are now li-
censed worldwide for the treatment of osteoarthritis (OA).
In the United States, IA-HA is indicated for pain relief in pa-
tients with OA of the knee who fail to respond to conserva-
tive non-pharmacologic therapy or simple analgesics (e.g.,
acetaminophen), and is included in the guidelines of the
American College of Rheumatology and the American
Academy of Orthopedic Surgery. The goal of therapy is to
reduce pain and improve physical function by temporarily
supplementing the viscosity and elasticity of synovial ﬂuid,
which are reduced in OA1. A course of treatment consists
of a series of three to ﬁve weekly intra-articular injections
with a viscoelastic solution of hyaluronan or its derivatives.
Efﬁcacy trials comparing IA-HA injections with saline injec-
tions demonstrate a statistically signiﬁcant difference over
a 3e6-month period, depending on the trial design2e5. In
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eﬁts for a year or longer6e8.
Commonly referred to as viscosupplementation, the ther-
apeutic beneﬁts of IA-HA injections are believed to be de-
pendent on the viscoelastic properties of the hyaluronan
injected9. It is widely believed that higher molecular weight
hyaluronan preparations will provide improved clinical ben-
eﬁts10,11. Questions regarding the importance of molecular
weight for IA-HA products are of particular clinical rele-
vance, because products can differ substantially in this pa-
rameter. Four IA-HA products are currently available in the
United States: Hyalgan (Fidia SpA, Padua, Italy), Su-
partz (Seikagaku Corporation, Tokyo, Japan), Orthovisc
(Anika Therapeutics, Woburn, MA) and Synvisc (Gen-
zyme Corporation, Cambridge, MA). Supartz, Hyalgan and
Orthovisc contain unmodiﬁed hyaluronan derived from
chicken combs, with molecular weight ranges speciﬁed on
their respective labels as 0.62e1.2 million Daltons for Su-
partz, 0.5e0.72 million Daltons for Hyalgan, and 1e2.9 mil-
lion Daltons for Orthovisc12e13. Synvisc is composed of two
cross-linked derivatives of hyaluronan (CL-HA): solid hylan
gel particles and soluble hylan molecules described as hav-
ing a molecular weight of 6 million Daltons14. Several recent
publications have noted acute local reactions after hylan
CL-HA injection15,16, particularly in patients receiving repeat
treatment17. Inﬂammatory reactions around hylan gel par-
ticles have also been histologically observed in synovial4
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consider safety differences among IA-HA products, and al-
ternate ways of producing high molecular weight hyalur-
onan for viscosupplementation.
All four of the IA-HA products currently available in the
United States are produced from chicken combs and there-
fore require the removal of inﬂammatory and immunogenic
impurities endogenous to the avian tissue source20. With
the aim of producing hyaluronan from a non-avian source,
methods have been developed to produce high molecular
weight hyaluronan using biological fermentation (Bio-
HA)21,22. EUFLEXXA bioengineered 1% sodium hyaluro-
nate (Ferring Pharmaceuticals, Inc., Suffern, NY) is a high
molecular weight IA-HA product produced by biological fer-
mentation. It has been approved in the European Union
since November 2000 and Israel since June 2001 and has
a molecular weight range of 2.4e3.6 million Daltons. The
high molecular weight of Bio-HA is achieved by careful con-
trol of the fermentation, recovery and puriﬁcation processes
and does not require the use of any cross-linking processes.
A small single-blind trial comparing Bio-HA with placebo
in 49 patients was conducted to estimate the efﬁcacy of
the product. The results were favorable but the study was
underpowered to declare statistically signiﬁcant differen-
ces23. Randomized clinical trials (RCTs) comparing IA-HA
products with placebo injections have not been uniformly
positive, and recent meta-analyses have likewise reached
divergent conclusions3,24,25. Because the ‘‘placebo’’ intra-
articular intervention in these RCTs can be considered an
active treatment in patients presenting with a synovial effu-
sion26, RCTs of IA-HA present methodological challenges
that remain incompletely resolved. Despite any ongoing
controversy, Food and Drug Administration (FDA) has re-
cently accepted RCTs designed to test for non-inferiority
as part of the marketing application for IA-HA products in
the United States.
In addition to the above consideration regarding non-infe-
riority, it was also deemed unethical to conduct a placebo-
controlled trial of Bio-HA in a setting where IA-HA products
are used in routine clinical practice. Our primary objective
was therefore limited to comparing the safety and effective-
ness of Bio-HA with those of CL-HA. This particular IA-HA
preparation was chosen for comparison because several
recent meta-analyses noted that the effect size for IA-HA
is greatest for the higher molecular weight preparations,
and CL-HA is the highest molecular weight hyaluronan
preparation currently available3,24,25.
Methods
TRIAL DESIGN
This was a multicenter, prospective, randomized, con-
trolled, double-blind (blinded patient/blinded evaluator)
study conducted in adult patients with symptomatic OA of
the knee. Patients were centrally randomized to receive ei-
ther EUFLEXXA (Bio-HA, Bio-engineered HA, Ferring
Pharmaceuticals, Inc., Suffern, NY) or Synvisc (CL-HA,
Hylan G-F 20, Genzyme Corporation, Cambridge, MA).
For the blinding procedure, unmarked boxes containing
three blister-packaged syringes of either Bio-HA or CL-HA
were delivered to the investigational sites. A computer-
generated randomization number was centrally assigned
to each box, and the randomization code was centrally
maintained by the sponsor and concealed from the study
sites. Randomization was blocked within the sites in groupsof four. The physician who performed evaluations was sep-
arate from the physician who performed injections in order
to maintain double-blinding (blinded patient, blinded evalua-
tor). All study-related case report forms recorded only the
randomization number.
Both products were administered as a course of three
2 ml injections administered weekly. Before administration
of each injection, any synovial ﬂuid that was present in
the knee was aspirated. Patients were advised to rest for
24 h following each injection, consistent with the label in-
structions for most IA-HA products. Assessments were per-
formed at screening, at baseline (prior to the ﬁrst injection),
and at 1, 2, 3, 6, and 12 weeks after the initial injection. Only
acetaminophen was permitted for rescue analgesia, up to
4 g daily, with usage quantitated by pill counts. Acetamino-
phen (as 500 mg tablets) was provided to study patients ac-
cording to the following schedule: 28 tablets were provided
at treatment initiation, week 1 and week 2; 84 tablets were
provided at week 3; and 168 tablets were provided at week
6. Non-steroidal anti-inﬂammatory drugs (NSAIDs) and
other non-acetaminophen pain medications were prohibited
during the study, and patients taking such agents were con-
sidered dropouts from the point of medication usage. The
study was carried out in accordance with the International
Conference on Hormonization (ICH) Guidelines for Good
Clinical Practice (May 1, 1996, amended September
1997) and the Declaration of Helsinki concerning medical
research in humans (1966).
PATIENTS
Patients were enrolled at 10 sites across Germany. The
study protocol and informed consent form were approved
by the relevant ethics committees. The study was open to
patients of either sex, age 50e80 years, with conﬁrmed
OA in one or both knees. OA diagnosis date and radiolog-
ical diagnosis date for the study knee and other knee
were recorded on the study case report form at baseline.
In patients with bilateral OA, the more symptomatic knee
was assigned as the study knee at the screening visit based
on the investigator’s clinical judgment. Patients were included
regardless of whether the tibio-femoral or patello-femoral
compartment was predominantly affected. Criteria for inclu-
sion were as follows: clinical evidence of chronic idiopathic
OA of the study knee according to the criteria of Altman; ra-
diologically veriﬁed OA of the study knee of grade 2 or 3 ac-
cording to a modiﬁcation of the grading system of Kellgren
and Lawrence (grade 2 deﬁned as deﬁnite osteophytes with
unimpaired joint space and grade 3 deﬁned as deﬁnite os-
teophytes with moderate joint space narrowing27); symp-
toms in the study knee for at least 1 year; willingness to
discontinue all OA treatments other than acetaminophen;
and moderate-to-severe knee pain as reﬂected by a visual
analog scale (VAS) pain score of 41e80 (on a scale of
0 mm [no pain] to 100 mm [worst pain]) for the average of
the ﬁve pain questions of the Western Ontario and McMas-
ter University Osteoarthritis Index (WOMAC Index)28, with
only one pain parameter permitted to be below 20 mm or
above 80 mm on the VAS. The ﬁve questions in the WO-
MAC Index pain scale are regarding pain during (1) walking
on a ﬂat surface, (2) going up and down stairs, (3) rest at
night, (4) sitting or lying, and (5) standing upright.
Patients were excluded from the study if they had sec-
ondary OA originating from a known injury to the knee,
rheumatoid arthritis, history of joint infection, dermatologic
disorders or skin infection in proximity to the study knee, os-
teonecrosis, chronic active ﬁbromyalgia, any inﬂammatory
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aminophen or hyaluronan. Patients were also excluded if
they had hyaluronan injections to the study knee within 6
months of the screening visit, corticosteroid injections and
surgery or arthroscopy to the study knee within 3 months
of screening. Non-ambulatory patients were excluded, as
judged by their inability to perform a 50-foot walk test. Pa-
tients with symptomatic OA of the hip or any other health
condition that would have interfered with the study assess-
ments were excluded, including patients with uncontrolled
hematological, cardiovascular, neoplastic, pulmonary, neu-
rological, renal, hepatic or systemic disease. Clinical labora-
tory values used as exclusion criteria were fasting blood
glucose concentration above 160 mg/dl, alkaline phospha-
tase above 250 U/l, alanine aminotransferase above 30 U/l,
or aspartate aminotransferase above 30 U/l. Patients were
precluded from participating in any other study during the
study period and during the 4 weeks prior to study
enrollment.
OUTCOME MEASURES
The primary effectiveness outcome measure was the
change in patients’ average score on the ﬁve questions
in the WOMAC Index pain scale, as measured on a
0e100 mm VAS for WOMAC subscale and full index analy-
ses. Secondary effectiveness measures included the full
WOMAC Index, the patients’ global assessment of treat-
ment and consumption of acetaminophen for pain relief as
quantitated by pill counts. For the patient global evaluations,
patients were asked to respond to the question ‘‘Are you sat-
isﬁed with the results of the injections?’’ and to grade their
response on the four-point ordinal scale: (1) dissatisﬁed,
(2) slightly satisﬁed, (3) satisﬁed or (4) very satisﬁed. These
provided the core outcomes measures of pain, function, and
global assessment suggested for OA clinical trials29,30.
Safety was assessed by collecting adverse event data at
each study visit, or whenever reported by patients. Adverse
events were deﬁned as any emergent sign or symptom,
whether related or unrelated to the study treatment. A seri-
ous adverse event was deﬁned as one that (1) was fatal, (2)
was life threatening, (3) resulted in persistent or signiﬁcant
disability/incapacity, (4) required or prolonged inpatient hos-
pitalization or (5) was a congenital anomaly or birth defect.
Adverse events were coded using MedDRA (Medical Dic-
tionary for Regulatory Activities) terminology, with coding
performed before unblinding the study. Patients’ blood
chemistry and hematological parameters were assessed
at the beginning and end of the study, and vital signs
were monitored for 30 min after each injection.
STATISTICAL METHODS
The analyses presented were performed on the intent-to-
treat (ITT) population, deﬁned as all patients randomized to
treatment and receiving at least one injection. All data pre-
sented are on an ITT/last observation carried forward basis.
Patients using prohibited pain medications during the trial
were considered dropouts from the point of medication
usage.
Patient demographic characteristics and disease status
at baseline were examined for treatment group comparabil-
ity using a one-way analysis of variance (ANOVA) for the
continuous variables and a CochraneManteleHaenszel
test, stratiﬁed by center, for the categorical variables.
The primary effectiveness outcome measure of the study
was the improvement in the WOMAC Index pain score frombaseline (week 0) to the last patient visit (week 12). The
study was powered to test for non-inferiority of Bio-HA com-
pared with CL-HA treatment, the latter having been licensed
by the FDA in the United States and therefore considered
as the active comparator. To compare the effectiveness of
the two treatments, a one-way ANOVA (Generalized Line-
ared Models (GLM) one-way ANOVA) was used to test
a null hypothesis, H0, deﬁned as:
H0: mR mTO 8.00
where mR was the mean outcome measure for the active
comparator and mT was the mean for the fermentation-
derived treatment. The value of 8 mm, which is less than
the minimal clinically important difference of 9e12 mm31,
was selected as the criterion for non-inferiority. Thus, if
a one-sided 95% upper conﬁdence boundary for the treat-
ment difference were less than the limit of the allowable
range (!4.16 mm), Bio-HA could be declared non-inferior
to CL-HA. The same approach was applied to the other
WOMAC indices.
The three WOMAC subscale scores, i.e., pain, stiffness,
and physical function were calculated as the averages of
the component item scores within each subscale. The total
WOMAC score was calculated as the average of the 24
component item scores (ﬁve in the pain subscale, two in
the stiffness subscale, and 17 in the physical function sub-
scale). A one-sample paired t test was used to compare the
within-group pain reductions from baseline to week 12. A
CochraneManteleHaenszel test was applied to the analy-
sis of the percentage of patients who were symptom free
(VAS score !20) as determined by the average score of
the ﬁve WOMAC pain parameters. Patients with a VAS
score of !20 were deﬁned as ‘‘symptom free’’ because
a 0e20 score on the VAS WOMAC pain subscale would
correspond to a ‘‘none’’ rating on the Likert WOMAC pain
subscale32, and because this deﬁnition was previously ap-
plied in trials of IA-HA products5,33. The consumption of res-
cue medication by the ITT population and patients with
unilateral knee OA was analyzed using the Cochranee
ManteleHaenszel test. Patient global overall assessments
evaluated at the end of the study were analyzed using Wil-
coxon’s two-sample test. Adverse events data for the two
groups were compared using a two-tailed Fisher’s exact
test, including the number of patients for whom joint effu-
sions were reported.
Sample size calculation
Assuming a standard deviation of 24 mm for the primary
outcome measure, the required sample size for the study
was estimated to be at least 250 patients for a power of
0.8 and a signiﬁcance level of 0.05 (one sided). Anticipating
protocol violators and early discontinuations for 25%, it was
projected that 320 patients should be enrolled.
Results
PATIENTS
Patient disposition for the study is presented in Fig. 1. Of
404 patients screened at study entry, a total of 321 patients
met the criteria for study entry and were randomized, 160 to
the Bio-HA group and 161 to the CL-HA group. Of the 83
patients not meeting the trial’s inclusion or exclusion crite-
ria, 17 were excluded because they did not meet the inclu-
sion criteria for WOMAC Index pain scores at baseline. Of
157Osteoarthritis and Cartilage Vol. 14, No. 2Randomization
Patients randomly allocated to treatment
n = 321
Investigational Drug Group
Allocated to Bio-HA treatment
n = 160
Lost to Follow-up
n = 2 
Discontinued Before Week 12
n = 2 (wishes to withdraw)
Completers
n = 156
Screening
n = 404
Excluded from Study
n = 83
Active Control Group
Allocated to active control (CL-HA) group
n = 161
Lost to Follow-up
n = 2 
Discontinued Before Week 12
n = 1 (adverse event)
Completers
n = 158
Fig. 1. Flow chart of patient disposition.the 321 patients randomized and receiving at least one in-
jection, 314 (98%) completed the ﬁnal study visit, with one
patient in the CL-HA group discontinued because of an ad-
verse event (effusion in Baker’s cyst in the injected knee,
possibly treatment related). Two patients in each group
were lost to follow-up and two patients in the Bio-HA group
decided to withdraw from the study for unknown reasons.
The analyses presented here were performed on the ITT
population, deﬁned as all patients randomized and receiv-
ing at least one injection.
Baseline characteristics for the ITTpopulationareprovided
in Table I. The patients were predominately female (2:1 ra-
tio), with a mean age of 63.2 years and a mean duration of
OA in the study knee of 58.9 months. Kellgren and Lawrence
radiologic grades were approximately equally distributed be-
tween grades II and III. All the patients met at least four of the
six Altman criteria for the diagnosis of knee OA. During the
physical examination prior to treatment, patients were eval-
uated with respect to presence of effusion in the study knee
(none/small/large). Eleven Bio-HA patients and 15 CL-HA
patients were judged to have a small effusion at baseline.
No signiﬁcant differences in baseline characteristics were
noted between the two study groups.
Baseline scores for the WOMAC Index pain, stiffness,
and physical function scales are shown in Table II. The
scores were similar for the two treatment groups and indic-
ative of moderate-to-severe impairment at baseline.
PRIMARY OUTCOME MEASURE
Table III provides the absolute change and percent im-
provement from baseline for the two study groups for each
question in the WOMAC pain subscale and for the average
of the ﬁve WOMAC pain questions (the primary outcome
measure). Both groups experienced statistically signiﬁcant
and clinically important improvements from baseline
(P! 0.0001). At the study end point, the mean improvement
in the primary effectiveness measure for the Bio-HA groupwas 29.9 mm (62% improvement from baseline), as com-
pared to 28.4 mm (55% improvement from baseline) for
the CL-HA group. The one-sided 95% upper conﬁdence
boundary for the treatment difference was 2.4 mm, which
Table I
Patient demographic baseline characteristics
Parameter Number of patients (%)
Bio-HA
(nZ 160)
CL-HA
(nZ 161)
Total
(nZ 321)
Gender
Female 99 (61.9%) 108 (67.1%) 207(64.5%)
Male 61 (38.1%) 53 (32.9%) 4(35.5%)
Age (years;
meanG Standard
Deviation (SD))
62.7G 7.5 63.7G 7.3 63.2G 7.4
Body Mass Index
(mean [kg/m2]G SD)
28.5G 4.7 27.8G 4.4 28.1G 4.6
Study knee
Left 73 (45.6%) 80 (49.7%) 153 (47.7%)
Right 87 (54.4%) 81 (50.3%) 168 (52.3%)
Kellgren and Lawrence grading system
(Grade 2) 88 (55.0%) 84 (52.2%) 172 (53.6%)
(Grade 3) 72 (45.0%) 77 (47.8%) 149 (46.4%)
Clinical symptomatology
Knee pain 160 (100%) 161 (100%) 321 (100%)
Stiffness !30 minutes 151 (94.4%) 151 (93.8%) 302 (94.0%)
Crepitus 154 (96.3%) 159 (98.8%) 313 (97.5%)
Bony tenderness 134 (83.8%) 145 (90.1%) 279 (86.9%)
Bony enlargement 72 (45.0%) 76 (47.2%) 148 (46.1%)
No palpable warmth 153 (95.6%) 149 (92.5%) 302 (94.0%)
Duration of OA in study knee
Months prior to
enrollment (meanG SD)
57.1G 45.9 60.7G 53.5 58.9G 49.8
There were no statistically signiﬁcant between-group differences
for any of the above parameters.
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prospective criteria for non-inferiority.
Figure 2 displays the mean change in VAS score for the
primary effectiveness measure during the full study period,
illustrating that clinically important reductions in pain contin-
ued after completion of the 15-day injection period for pa-
tients in both treatment groups. By the 12-week study end
point, the mean score for the WOMAC pain average had
dropped to approximately 20 mm in both treatment groups.
The percentage of patients whose VAS score for the av-
erage of the ﬁve WOMAC pain questions was!20 (deﬁned
previously as ‘‘symptom-free’’ patients) was compared for
the two treatment groups in a post hoc analysis. At the
study end point, 63% of patients in the Bio-HA group
were symptom free compared to 52% in the CL-HA group,
a statistically signiﬁcant difference (PZ 0.038; 95% Conﬁ-
dence Interval (C.I.)Z 0.3%, 21.7%) (Table IV). This differ-
ence between the groups with respect to symptom-free
patients for the WOMAC pain subscale was conﬁrmed by
evaluating the percentage of patients with an average WO-
MAC function subscale score less than !20 mm at week
12: 64.3% (101/157) for the Bio-HA group vs 47.5% (75/
158) for the CL-HA group (PZ 0.003).
SECONDARY OUTCOME MEASURES
WOMAC Index
The improvement in the full WOMAC Index score (pain,
stiffness and function subscales) over the study period is il-
lustrated in Fig. 3. Table V provides the average
Table II
Mean baseline score for full WOMAC Index (100 mm VAS)
WOMAC Index scores Mean baseline VAS score (GSE)
Bio-HA
(nZ 160)
CL-HA
(nZ 161)
Average of 5 WOMAC
Index pain scores
49.2G 1.1 51.9G 1.1
Average of 2 WOMAC
Index stiffness scores
43.2G 1.5 47.8G 1.5
Average of 17 WOMAC Index
physical function scores
47.0G 1.2 50.8G 1.2
Average scores for full
WOMAC Index (pain,
stiffness and physical function)
47.2G 1.1 50.8G 1.1
There were no statistically signiﬁcant between-group differences
in any baseline parameter.improvement for the three subscales of the WOMAC Index
as a percent improvement from baseline and the percent
improvement in the aggregate WOMAC score. The Bio-
HA group experienced a mean improvement of 27.3 mm
in the full WOMAC Index (59% improvement from baseline)
compared to 25.9 mm (52%) for the CL-HA group. There
were no signiﬁcant differences between the two groups
with respect to the WOMAC Index or its subscales.
Patient global assessments
The results of the patient global assessments performed at
the study end point (12 weeks) are illustrated in Table VI. Ap-
proximately 94% of patients reported some degree of satis-
faction with treatment and approximately 80% reported
being either satisﬁed or very satisﬁed in both study groups.
Analysis across all categories of improvement revealeda sta-
tistically signiﬁcant difference favoring the Bio-HA group
(PZ 0.03). The between-group difference was apparent
when comparing the percentage of patients who reported be-
ing ‘very satisﬁed’ (50% in the Bio-HA group compared to
37% in the CL-HA group), and corroborates the higher per-
centage of ‘‘symptom-free’’ patients found in the Bio-HA
group with respect to the WOMAC Index pain scale.
Use of rescue medication
The use of rescue medication (acetaminophen) in the
study population is detailed in Table VII for all evaluation
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Fig. 2. Change from baseline in mean WOMAC Index pain sub-
scale VAS scores throughout the study period (average of the
ﬁve WOMAC pain scale questions). Error bars represent standard
error of the mean. VASZ 100 mm VAS.Table III
Reduction from baseline in individual questions and aggregate scores for the WOMAC pain subscale (100 mm VAS) at week 12
WOMAC Index pain scores Mean* (%) reduction from baseline (GStandard Error (SE))
Bio-HA (nZ 160) CL-HA (nZ 161)
Walking on a ﬂat surface 31.2G 2.0 (59.7G 4.4) 28.7G 2.0 (49.5G 4.4)
Going up and down stairs 36.1G 2.2 (58.0G 3.7) 32.2G 2.2 (46.2G 3.7)
Rest during night 25.6G 1.9 (51.0G 5.8) 27.1G 1.9 (48.4G 5.8)
Sitting or lying 26.4G 1.9 (55.1G 5.0) 25.7G 1.9 (44.3G 5.0)
Standing upright 30.1G 2.1 (59.3G 4.7) 28.4G 2.1 (44.9G 4.7)
Average of ﬁve WOMAC Index pain scores 29.9G 1.7 (61.5G 3.0) 28.4G 1.7 (54.2G 3.0)
Both treatment groups demonstrated statistically signiﬁcant and clinically meaningful improvements from baseline (P! 0.0001). At the
study end point, the mean improvement in the primary effectiveness measure (average of ﬁve WOMAC Index pain scores) for Bio-HA was
29.9 mm (62% improvement from baseline) compared to 28.4 mm (54% improvement from baseline) for CL-HA.
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the patient subgroup with unilateral knee OA. For the full
study population, 61% (97/159) of Bio-HA and 73% (118/
161) of CL-HA patients required rescue medication at
some point during the study (PZ 0.013). On average,
Bio-HA patients used 4.2 acetaminophen tablets per week
during the trial, compared to 5.8 tablets per week for CL-
HA patients. Over the full study period, the CL-HA patients
used signiﬁcantly more acetaminophen tablets than the Bio-
HA patients (Bio-HA, mean of 51.0 tablets; CL-HA, mean of
67.7 tablets; P! 0.001; two-tailed, two-sample t test) (Ta-
ble VII). In the subgroup analysis performed on patients
with unilateral OA, 49% of Bio-HA patients (33/67) used res-
cue medication at any time in the 12-week study period,
compared to 82% of CL-HA patients (59/72), a statistically
signiﬁcant difference (PZ 0.001).
SAFETY OUTCOMES
Adverse events were coded using MedDRA terminology
before the study was unblinded. A total of 196 treatment-
emergent adverse events were reported in 119 patients;
33.8% of Bio-HA patients (54/160) and 40.4% of CL-HA pa-
tients (65/161) experienced an adverse event. The severity
of these adverse events was coded by the investigator as
mild or moderate in 77/91 cases (84.6%) for the Bio-HA
group and 95/105 cases (90.5%) for the CL-HA group.
There were no deaths in either treatment group. Five seri-
ous adverse events were reported during the trial, three
in the Bio-HA group and two in the CL-HA group; none
of these events were considered related to the study treat-
ment, and none resulted in withdrawal of the patient from
Table IV
Number of patients who were symptom free (VAS score below
20 mm) in WOMAC pain questions (individual categories and aver-
age scores) at week 12*
WOMAC Index
pain scores
Number (%) of patients that
were symptom free (VAS
score between 0 and 20 mm)
Bio-HA
(nZ 160)
CL-HA
(nZ 161)
Walking on a ﬂat surface 101 (63.1%) 88 (54.7%)
Going up and down stairs 80 (50.0%) 61 (37.9%)
Rest during night 117 (73.1%) 100 (62.1%)
Sitting or lying 109 (68.1%) 98 (60.9%)
Standing upright 104 (65.0%) 90 (55.9%)
Average of ﬁve WOMAC Index
pain scores
101 (63.1%)* 84 (52.2%)*
*At the study end point, 63.1% of Bio-HA patients were symptom
free (VAS score for the average of the ﬁve WOMAC pain questions
was!20 mm) compared to 52.2% in the CL-HA group (PZ 0.038;
95% C.I.Z 0.3%, 21.7%).the study. No signiﬁcant systemic reactions were noted
for either group (one investigator considered three inciden-
ces of high blood pressure in the Bio-HA group to be re-
motely related to the treatment, with no explanation).
There were no signiﬁcant within or between-group changes
in mean values for clinical laboratory evaluations or vital
signs over the course of the study.
Adverse events occurring in more than 5% of patients are
listed in Table VIII. The most commonly reported events
were arthralgia, back pain and joint effusion. The incidence
of joint effusion was signiﬁcantly higher in the CL-HA group
(8.1% vs 0.6%; PZ 0.0015), with one episode reported in
one patient for the Bio-HA group compared with 15 epi-
sodes in 13 patients for the CL-HA group. One patient in
the CL-HA group was reported to have an effusion and
then developed a Baker’s cyst (possibly attributed to study
therapy); this patient withdrew from the study.
Discussion
Several IA-HA products are currently available in the
United States for the treatment of knee OA, and more
than 20 additional products are available in other parts of
the world. These preparations can differ signiﬁcantly in their
molecular weight, purity, and concentration12e14,34. It is
therefore essential to identify any clinically important differ-
ences among IA-HA preparations and establish standards
that ensure safety and effectiveness.
The trial reported here compares two high molecular
weight hyaluronan preparations used for treating patients
with OA of the knee. Because the IA-HA products tested are
derived from different sources (microbial fermentation vs ex-
traction from avian tissue), and because the avian-source
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(pain, stiffness, and function scales). Error bars represent standard
error of the mean. VASZ 100 mm VAS.Table V
Reduction from baseline in score for full WOMAC Index (100 mm VAS) at week 12
WOMAC Index scores Mean* (%) reduction from baseline (GSE)
Bio-HA (nZ 160) CL-HA (nZ 161)
Average of ﬁve WOMAC Index pain scores 29.9G 1.7 (61.5G 3.0) 28.4G 1.7 (54.2G 3.0)
Average of two WOMAC Index stiffness scores 24.8G 1.9 (52.8G 10.6) 25.4G 1.9 (30.3G 10.5)
Average of 17 WOMAC Index physical function scores 26.9G 1.6 (57.6G 3.1) 25.2G 1.6 (49.4G 3.1)
Average scores or full WOMAC Index (pain, stiffness and physical function) 27.3G 1.6 (58.8G 3.0) 25.9G 1.6 (51.1G 3.0)
At the study end point, the Bio-HA patients experienced a mean improvement from baseline of 59% in the full WOMAC Index compared to
52% for the CL-HA group. There were no statistically signiﬁcant between-group differences.
160 M. Kirchner and D. Marshall: Hyaluronan in the osteoarthritic kneehyaluronan uses cross-linking processes to increase molec-
ular weight by chemical derivatization, it is essential to eval-
uate any clinically important differences between the two IA-
HA products. This trial was designed and powered to test
for non-inferiority and met the predeﬁned criteria for demon-
strating that the effectiveness of Bio-HA was not inferior to
that of CL-HA for the primary variable (change in average
VAS score on the ﬁve questions in the WOMAC Index
pain scale). With respect to the trial’s secondary outcome
measures, statistically signiﬁcant differences favoring the
Bio-HA group were found for the patient global assess-
ments and the percentage of patients requiring acetamino-
phen as rescue medication. The latter is notable because it
indicates that the similar effectiveness observed for the pri-
mary outcome measure and differences in effectiveness for
some secondary outcome measures were observed despite
the greater usage of acetaminophen in the CL-HA group.
Statistically signiﬁcant and clinically important differences
in safety outcomes were also found in the trial, though it
was not speciﬁcally powered to detect such differences.
The number of local reactions accompanied by effusion
was signiﬁcantly higher in the CL-HA group compared to
the Bio-HA group (15 effusions in 13 patients for CL-HA,
compared to one effusion). These data corroborate recent
reports of acute local inﬂammatory reactions to CL-HA in-
jection15e19,35, but are the ﬁrst clear demonstration of this
important sequela in a RCT setting. Because effusions
may necessitate arthrocentesis, the reduced number of ef-
fusions in the Bio-HA group suggests that patients treated
with Bio-HA are at reduced risk for local reactions requiring
physician intervention and follow-up. Treatment of adverse
reactions can add signiﬁcantly to the total cost of IA-HA
treatment, suggesting that Bio-HA may also have health
economic advantages over CL-HA.
Table VI
Subjective patient assessment of treatment*
Overall patient
assessment of treatment
Bio-HA CL-HA Total
No. of patients assessed 157 (100%) 158 (100%) 315 (100%)
Dissatisﬁed 12 (7.6%) 11 (7.0%) 23 (7.3%)
Slightly satisﬁed 18 (11.5%) 28 (17.7%) 46 (14.6%)
Satisﬁed 48 (30.6%) 61 (38.6%) 109 (34.6%)
Very satisﬁed 79 (50.3%)* 58 (36.7%)* 137 (43.5%)
*At the end of the study, there was a statistically signiﬁcant be-
tween-group difference in favor of Bio-HA (PZ 0.03) patients
who were very satisﬁed with treatment results.Several recent meta-analyses have evaluated the effect
size when IA-HA is compared with saline injections3,24,25.
Though the magnitude of the effect size remains a subject
of debate, all of these meta-analyses reported a statistically
signiﬁcant difference favoring IA-HA over saline injections.
The absence of an adequately powered, placebo-controlled
RCT for Bio-HA remains a limitation on the interpretation of
our data; however, the results of these recent meta-analy-
ses support the decision to perform the clinical study re-
ported here as a non-inferiority trial.
Managing patients with OA of the knee presents a grow-
ing challenge to clinicians and health policy decision mak-
ers. Pharmacotherapy with NSAIDs remains a mainstay of
therapy, despite the iatrogenic morbidities of long-term
NSAID administration36,37. Safety concerns associated
with the use of systemic medications are exacerbated by
comorbidities in the affected population and potentially
dangerous drug interactions. The trial data presented
here provide evidence that Bio-HA can reduce pain and
improve function in patients with knee OA without the iat-
rogenic local reactions associated with cross-linked IA-HA
products.
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Table VIII
Adverse events occurring in more than 5% of patients (any
causality)*
Adverse event Bio-HA (nZ 160) CL-HA (nZ 161)
No. of
patients (%)
No. of
events
No. of
patients (%)
No. of
events
Total 54 (33.8) 91 65 (40.4) 105
Arthralgia 14 (8.8) 18 17 (10.6) 19
Back pain 8 (5.0) 8 11 (6.8) 11
Joint effusion 1 (0.6)* 1 13 (8.1)* 15
*There was a statistically signiﬁcant between-group difference
between the number of Bio-HA and CL-HA patients with joint effu-
sions (PZ 0.0015). Adverse event coding was performed while re-
sults were blinded.Table VII
Number (%) of patients using rescue medication (acetaminophen)*
Time Single knee All subjects
Bio-HA CL-HA Bio-HA CL-HA
Week 1 19/67 (28.4%) 36/71 (50.7%) 50/158 (31.6%) 71/156 (45.5%)
Week 2 16/66 (24.2%) 35/71 (49.3%) 47/157 (29.9%) 78/160 (48.8%)
Week 3 22/67 (32.8%) 33/71 (46.5%) 55/158 (34.8%) 75/160 (46.9%)
Week 6 24/67 (35.8%) 41/69 (59.4%) 65/158 (41.1%) 89/156 (57.1%)
Week 12 23/65 (35.4%) 42/67 (62.7%) 64/154 (41.6%) 91/155 (58.7%)
During study 33/67 (49.3%) 59/72 (81.9%) 97/159* (61.0%) 118/161* (73.3%)
*There was a statistically signiﬁcant between-group difference in favor of Bio-HA (PZ 0.013) in the number of patients who required rescue
medications during the study. Total patient numbers varied throughout the course of the study due to loss of pill bottles by individual patients.
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